Major Depressive Disorder

FDA accelerates psychedelic drug development to advance agents for TRD, PTSD, and AUD.

Explore GLP-1 agonists and their "truly transformative" role in psychiatry in this podcast.

In this CME article, learn how depression hides in organ failure, transplants, neurologic disease, and hormonal shifts—plus screening tips and safer treatment choices.

Learn more about the treatment of depression, selective serotonin reuptake inhibitors, and pregnancy in this podcast.

Deep intracranial frequency stimulation 77.5 Hz high-gamma approach was associated with statistically significant reductions in self-injury behaviors and depressive symptoms in female adolescents with nonsuicidal self-injury.

BPL-003 phase 2a part 2 results show reductions in depression symptoms.

An interview with Felice Jacka, OAM, PhD, on the rapidly developing field of nutritional psychiatry.

Intranasal BPL-003 shows rapid, sustained depression relief in treatment-resistant patients.

Psychedelic therapies surge in trials, but safety varies by substance—learn key benefits, risks, and why psychiatric history raises complications.

FDA feedback for CYC-126: anesthetic therapy with live EEG guidance aims to deliver precise relief for treatment-resistant depression.

IV DMT psychedelic SPL026 reduces major depression in phase 2a.

Phase 3 trial shows COMP360 psilocybin rapidly reduces treatment-resistant depression symptoms with durable effects and good safety, as Compass moves toward FDA review.

Adjunctive lithium sharply reduces relapse and suicidal ideation, and attempts in patients with bipolar disorder and major depressive disorder.

How ketamine sparks a glutamate-driven BDNF burst, reshaping prefrontal connectivity in depression and revealing the glutamate–GABA partnership.

Brief interpersonal therapy in pregnancy sharply lowers depression and postpartum relapse for a year—offering clinicians a fast, safe option.

Learn how bupropion can trigger dose-related tinnitus and when lowering or stopping the antidepressant brings relief, with real-world clinical guidance.

New evidence reframes antidepressant withdrawal: how common, how severe, and how to taper safely without mistaking symptoms for relapse.

Antidepressant withdrawal often mimics relapse; learn why hyperbolic tapering, informed consent, and slow cut-and-hold deprescribing reduce harm.

Long-term antidepressant use rises in Australia, surging among individuals aged 10 to 24, with more off-label sleep and pain prescribing raising safety and withdrawal concerns.

Research reveals that individuals with preexisting mental illnesses face a significantly higher risk of developing long COVID, emphasizing the need for targeted support.

Meta-analysis reveals benefit of anti-inflammatory treatment for depression and anhedonia in individuals with inflammatory phenotype.

LB Pharmaceuticals initiates a phase 2 trial for LB-102, a promising treatment for bipolar depression, aiming to address unmet needs in mood disorders.

What is new in research on major depressive disorder?

Eric Nestler, MD, PhD, reflects on his research and new role as dean of the Icahn School of Medicine.

Explore how lifestyle psychiatry transforms depression treatment through nutrition, exercise, sleep, and social connections for holistic recovery and resilience.